ALXO Stock Forecast: ALX Oncology Holdings, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for ALX Oncology Holdings, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 18 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores ALX Oncology Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (66): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (22): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ALXO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ALXO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Mar 2026 | Wells Fargo | Initiates | Overweight | $5.00 |
| 10 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 21 May 2025 | UBS | Maintains | Buy | — |
| 9 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | Stifel | Maintains | Hold | — |
| 6 Mar 2025 | Jefferies | Upgrade | Buy | — |
| 6 Mar 2025 | Piper Sandler | Maintains | Overweight | — |
| 27 Jan 2025 | UBS | Maintains | Buy | — |
| 24 Jan 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 24 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Dec 2024 | Jefferies | Downgrade | Hold | — |
| 18 Dec 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 18 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 16 Aug 2024 | UBS | Maintains | Buy | — |
| 13 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 Aug 2024 | Stifel | Reiterates | Hold | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ALXO.
This page is one stock. Monday covers all of them.
ALXO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ALXO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, ALX Oncology Holdings, Inc. returned −30.6% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ALXO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.2×
- EV / EBITDA
- —
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −94.4%
- Return on assets
- −43.8%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ALX Oncology Holdings, Inc. has a market value of $139.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$80.9M.
Diluted earnings per share, trailing twelve months: −$1.13.
Free cash flow in the twelve months to 30 June 2026: −$71.0M.
ALX Oncology Holdings, Inc. employs 49 people.
Data provided by Twelve Data
ALXO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ALXO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own ALX Oncology Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ALXO
What is the ALXO stock price forecast for 2026-2027?
The median 12-month analyst price target for ALX Oncology Holdings, Inc. is $4, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ALXO stock a buy right now?
Of the 7 analysts covering ALX Oncology Holdings, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ALX Oncology Holdings, Inc. 40 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ALXO?
As at 18 Nov 2026, ALX Oncology Holdings, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (66 of 100).
Will ALXO stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $4, and Ticker Nerd's factor model ranks ALX Oncology Holdings, Inc. 40 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ALXO stock forecast for 2030?
No analyst covering ALX Oncology Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALXO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.
How has ALXO stock performed over the past year?
ALX Oncology Holdings, Inc. returned -30.6% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ALX Oncology Holdings, Inc. do?
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer. Its lead program, evorpacept, is designed to block the CD47 pathway and is being studied in combination with other anti-cancer treatments across multiple solid tumor and blood cancer indications.
About ALX Oncology Holdings, Inc.
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer. Its lead program, evorpacept, is designed to block the CD47 pathway and is being studied in combination with other anti-cancer treatments across multiple solid tumor and blood cancer indications. The company’s pipeline also includes ALX2004, an epidermal growth factor receptor-targeted antibody-drug conjugate under development for EGFR-expressing tumors. ALX Oncology’s work centers on protein engineering, combination therapy research, and clinical studies aimed at addressing difficult-to-treat cancers. Based in South San Francisco, California, the company operates within the broader oncology drug development market and collaborates with clinical trial sites and research partners to advance its product candidates.
CEO Mr. Jason W. Lettmann · 49 employees · United States · https://www.alxoncology.com